Pulmonary Arterial Hypertension

The AJMC® Pulmonary Arterial Hypertension compendium is a comprehensive resource for clinical news and expert insights for the progressive disorder, which is characterized by high blood pressure in the arteries that go from the heart to the lungs.

Latest News

Echocardiography | Image Credit: Tamer-stock.adobe.com
TPIP a Potential Game-Changer for Prostanoid Therapy in PAH

June 11th 2025

Treprostinil palmitil inhalation powder (TPIP) for pulmonary arterial hypertension (PAH) showed promising results in a midstage clinical trial, significantly improving key measures of heart and lung function.

Anjali Vaidya, MD, FACC, FASE, FACP | Image Credit: Temple University Hospital
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide

June 4th 2025

PAH X-ray with pen | Image credit: Dzmitry – stock.adobe.com
Sotatercept for PAH Maintains Safety, Reduced Mortality in Long-Term Follow-Up

May 30th 2025

Ultrasound and a stethoscope | Image Credit: © Natalya Lys-stock.adobe.com
Suboptimal Care for PAH Persists Among Women

May 28th 2025

Heartbeat EKG | Image Credit: © Tima-stock.adobe.com
Impedance Cardiography Offers Noninvasive Insight Into PAH Progression

May 15th 2025

Transforming PAH Management Through Innovation and Strategic Care

Learn how novel therapies, early diagnosis, and personalized treatment approaches are advancing PAH care while addressing clinical needs, patient preferences, and economic impact.

AJMC Stakeholder Summit logo displayed on a light blue and white scientific background with hexagonal molecular graphics and connecting lines.

More News

blue heart and echocardiogram
March 21st 2021

Survey Finds Unmet Needs Despite Good HRQOL for Patients With PAH

Skylar Jeremias
Despite patients with pulmonary arterial hypertension reporting good quality of life and low symptom severity, functional limitations persisted, suggesting improvements to the patient experience are needed, according to researchers.
Patients With PAH Have Similar Incidence of COVID-19, but Potentially Worse Outcomes
March 18th 2021

Patients With PAH Have Similar Incidence of COVID-19, but Potentially Worse Outcomes

Laura Joszt, MA
Patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension had similar incidence of COVID-19, but the impact on clinical operations at the centers that treat these patients was substantial.
Nasal cannula for oxygen
March 9th 2021

Oxygen Has Potential Benefits as a Therapy for Pulmonary Arterial Hypertension

Laura Joszt, MA
A review of evidence finds that oxygen therapy may be beneficial for all patients with pulmonary arterial hypertension, not just those who develop severe hypoxemia.
Newly Diagnosed Patients With PAH Benefit From Earlier Initiation of Therapy
March 7th 2021

Newly Diagnosed Patients With PAH Benefit From Earlier Initiation of Therapy

Laura Joszt, MA
Patients with pulmonary arterial hypertension (PAH) who are treated with selexipag within 6 months of their diagnosis had a reduced risk of morbidity/mortality compared with patients who were treated longer than 6 months after diagnosis.
Pulmonary Arterial Capacitance Is a Strong Predictor of Mortality in PAH, PH-LHD
March 5th 2021

Pulmonary Arterial Capacitance Is a Strong Predictor of Mortality in PAH, PH-LHD

Laura Joszt, MA
Targeting pulmonary arterial capacitance or compliance can improve overall survival and quality of life in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension secondary to left heart disease (PH-LHD).
Real-World Study Finds Oral Combination Therapy of Macitentan, Riociguat, and Selexipag Effective in PAH
March 2nd 2021

Real-World Study Finds Oral Combination Therapy of Macitentan, Riociguat, and Selexipag Effective in PAH

Laura Joszt, MA
Triple oral combination therapy with macitentan, riociguat, and selexipag may be a promising strategy to treat patients with low/intermediate-risk pulmonary arterial hypertension (PAH), and possibly even patients with high-risk PAH.
Diagnosing and Treating Systemic Sclerosis With PAH Remains Challenging
February 27th 2021

Diagnosing and Treating Systemic Sclerosis With PAH Remains Challenging

Laura Joszt, MA
While diagnostic algorithms have evolved in the last decade, there remains an urgent need for innovative therapeutic options to treat systemic sclerosis with pulmonary arterial hypertension.
Understanding Mortality Risk in Pediatric Pulmonary Arterial Hypertension
February 26th 2021

Understanding Mortality Risk in Pediatric Pulmonary Arterial Hypertension

Larry Hanover
The study examined various factors used in an internationally developed risk stratification strategy to assess which ones had evidence of being significant in determining a child’s prognosis from the deadly disease.
Which Agents Are Linked to Drug- and Toxin-Induced PAH?
February 20th 2021

Which Agents Are Linked to Drug- and Toxin-Induced PAH?

Jaime Rosenberg
In their recently published review, the researchers offer a detailed look at the drugs and toxins associated with drug- and toxin-induced pulmonary arterial hypertension (PAH), as various associations have come to light in recent decades.
A Roadmap for Managing Right Ventricular Failure in PH
February 19th 2021

A Roadmap for Managing Right Ventricular Failure in PH

Jaime Rosenberg
The researchers prefaced their study by highlighting that pulmonary arterial hypertension (PAH) and all forms of PH continue to be highly morbid and sometimes fatal, particularly in cases requiring hospitalization in the intensive care unit.
Doctors consulting
February 12th 2021

Temporary Treatment With IV Selexipag Is Safe for Patients With PAH

Larry Hanover
A temporary switch from oral to intravenous (IV) selexipag is safe and well tolerated in the treatment of pulmonary arterial hypertension (PAH).
Case Study Describes Development of PAH During Multiple Myeloma Therapy
February 11th 2021

Case Study Describes Development of PAH During Multiple Myeloma Therapy

Larry Hanover
Patients being treated for multiple myeloma with carfilzomib should have cardiopulmonary screening and monitoring due to the risk of developing pulmonary arterial hypertension (PAH).
Machine Learning-Based Approach to CMR Imaging Analysis Proves Beneficial for PAH Diagnosis
February 5th 2021

Machine Learning-Based Approach to CMR Imaging Analysis Proves Beneficial for PAH Diagnosis

Jaime Rosenberg
The approach, the researchers say, allows for rapid and accurate diagnosis of pulmonary arterial hypertension (PAH) by analyzing cardiac magnetic resonance (CMR) images without manual image segmentation.
Researchers Highlight Progress, Remaining Unknowns in Genetics of PAH
January 30th 2021

Researchers Highlight Progress, Remaining Unknowns in Genetics of PAH

Jaime Rosenberg
As up to 1 in 3 patients with pulmonary arterial hypertension have unknown explanations for their disease and its pathobiology, a team of researchers is exploring the genetic architecture of pulmonary arterial hypertension (PAH).
Prevalence, Incidence of PAH in SSc Steady Over Time, Report Says
January 29th 2021

Prevalence, Incidence of PAH in SSc Steady Over Time, Report Says

Allison Inserro
The authors said this study included more up-to-date definitions of diagnosing pulmonary arterial hypertension (PAH), which is an increasing factor in deaths from systemic sclerosis (SSc).
Low SES, Patient Barriers Hinder PAH Exercise Rehab
January 22nd 2021

Low SES, Patient Barriers Hinder PAH Exercise Rehab

Gianna Melillo
Lower socioeconomic status (SES) and barriers related to the perceived need for exercise rehabilitation were associated with decreased referral to rehabilitation among patients with pulmonary arterial hypertension (PAH).
Ensuring a Path of Success for Drug Repurposing in PAH
January 14th 2021

Ensuring a Path of Success for Drug Repurposing in PAH

Jaime Rosenberg
Among the viewpoints offered by the authors to overcome barriers in solving unmet needs in pulmonary arterial hypertension (PAH) are preclinical pipelines for drug repurposing, working around challenges in early-stage trial design, and refining target selection and demonstration of engagement.
Identifying Predictors of Mortality for Adults With PAH, CHD
January 9th 2021

Identifying Predictors of Mortality for Adults With PAH, CHD

AJMC Staff
A recent study sought to examine the course of these patients after the age of 40, and to identify possible risk factors for a worse prognosis.
Researchers Identify Predictors of Pulmonary Hypertension Among Patients With MPNs
December 29th 2020

Researchers Identify Predictors of Pulmonary Hypertension Among Patients With MPNs

Laura Joszt, MA
Survival among patients with myeloproliferative neoplasm (MPN)–associated pulmonary hypertension (PH) is generally short, although the true prevalence of PH among these patients is poorly understood.
Woman and man on balance scale
December 26th 2020

Sex, Genetics, and the Relationship Between the Two in Pulmonary Arterial Hypertension

Jaime Rosenberg
Although research has cemented BMPR2 mutations as having associations with the development of pulmonary arterial hypertension, the germline mutations are not the only culprit.
Neon depiction of lungs
December 22nd 2020

Researchers Outline Pathological Mechanisms, Potential Therapeutic Targets in PAH

Jaime Rosenberg
In a new review, researchers outline both the underlying pathological mechanisms and potential therapeutic targets in pulmonary arterial hypertension (PAH).
Physicians’ Risk Assessment in Patients With PAH Often Varies From Objective Measures
December 17th 2020

Physicians’ Risk Assessment in Patients With PAH Often Varies From Objective Measures

Jared Kaltwasser
In roughly half of cases assessed, physicians underestimated a patients’ risk, according to multiparametric objective risk-assessment tools.
NIH hypertension
December 15th 2020

Patients With PAH Fluctuate Between Feelings of Devastation and Hope

Skylar Jeremias
In an abstract presented at CHEST 2020, investigators revealed that the emotions that patients with pulmonary arterial hypertension (PAH) regarding their illness are more complex than previously thought.
Review Analyzes Evidence Base for Multidrug Approach in PAH
December 12th 2020

Review Analyzes Evidence Base for Multidrug Approach in PAH

Jaime Rosenberg
A review published earlier this year examines the rationale and evidence for using a multidrug approach in pulmonary arterial hypertension (PAH).
Studies Highlight Multiple Underlying Etiologies of PAH, Predictive Factors of PAA
December 10th 2020

Studies Highlight Multiple Underlying Etiologies of PAH, Predictive Factors of PAA

Jaime Rosenberg
A group of researchers published their research on the various underlying etiologies of pulmonary arterial hypertension (PAH), as well as predictive factors of pulmonary artery aneurysms (PAAs).
Silhouette of person exercising superimposed on echocardiography
December 5th 2020

A Look at the Use of Echocardiography to Assess Macitentan Effects, Predict Mortality in PAH

Jaime Rosenberg
Two studies presented at CHEST 2020 assessed the impact of macitentan on cardiac function in pulmonary arterial hypertension (PAH) and determined what role reproducible exercise echocardiographic parameters have in predicting survival.
Selexipag Improves Outcomes in Patients With CTD-PAH
December 3rd 2020

Selexipag Improves Outcomes in Patients With CTD-PAH

AJMC Staff
Use of selexipag in patients with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) resulted in outcomes similar to those seen in patients with idiopathic PAH, despite the traditionally poorer prognosis of CTD-PAH.
Real-World Data of Combination Therapy With Macitentan to Treat PAH
November 27th 2020

Real-World Data of Combination Therapy With Macitentan to Treat PAH

Laura Joszt, MA
Combination therapy plays a central role in treating pulmonary arterial hypertension (PAH), and 2 abstracts presented at the CHEST annual meeting highlighted real-world treatment patterns.
Study of 2 Treatments for PAH Finds 1 Reduces Risk of Hospitalization
November 25th 2020

Study of 2 Treatments for PAH Finds 1 Reduces Risk of Hospitalization

Jaime Rosenberg
Compared with treprostinil, selexipag carried a 47% reduced risk of pulmonary arterial hypertension (PAH)-related hospitalization and 46% reduced risk of all-cause hospitalization.
Risk of Death Differs for Elderly Patients With PAH Taking Endothelin Receptor Antagonists
November 20th 2020

Risk of Death Differs for Elderly Patients With PAH Taking Endothelin Receptor Antagonists

Laura Joszt, MA
The mortality risk differs for the 3 endothelin receptor antagonists approved to treat pulmonary arterial hypertension (PAH) in elderly patients; however, a direct comparison in a controlled trial is still needed to confirm results.
<1
...
456789>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo